Compare ADMA Biologics Inc (ADMA) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Cognizant Technology Solutions Corp — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Cognizant Technology Solutions Corp trades at $42.43 (market cap $20.78B). The key difference: Cognizant Technology Solutions Corp is far larger — about 9.8× ADMA Biologics Inc's market cap, and Cognizant Technology Solutions Corp pays a 3% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CTSH | |
|---|---|---|
Market Cap | $2.13B | $20.78B |
Sector | Health | Technology |
52-Week High | $20.38 | $86.70 |
52-Week Low | $7.60 | $38.73 |
Enterprise Value | $2.20B | $20.36B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Cognizant Technology Solutions (CTSH) trades at $43.94, up 4.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.97 and net margin of 10.41%, supported by $21.11B revenue in 2025. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning CTSH for growth in enterprise AI solutions.
Outlook remains positive with a consensus price target of $67.58, implying 54% upside, though near-term risks include soft IT demand and margin pressures. Institutional sentiment is mixed with 43% buy ratings, but the valuation discount and AI expansion present a compelling opportunity for long-term investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
